External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Camlin Fine Sciences (CFS) reported highest ever quarterly &amp; half yearly revenues for Q2FY23.</li><li>Consolidated revenues stood at Rs 483 Cr, up 55% YoY (our estimate: Rs 389 Cr).</li><li>The company’s EBITDA Margins contracted by 72 bps q-o-q to 11.4% (our estimate: 10.5%) to report absolute EBITDA of Rs55 Cr, up 143%/18% y-o-y/q- o-q, this included the net effect of 15 Cr from CFS Europe.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Camlin Fine Sciences (CFS) reported highest ever quarterly &amp; half yearly revenues for Q2FY23.Consolidated revenues stood at Rs 483 Cr, up 55% YoY (our estimate: Rs 389 Cr).The company’s EBITDA Margins contracted by 72 bps q-o-q to 11.4% (our estimate: 10.5%) to report absolute EBITDA of Rs55 Cr, up 143%/18% y-o-y/q- o-q, this included the net effect of 15 Cr from CFS Europe.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Camlin Fine Sciences Ltd - Strong Performance Across Subsidiaries/Geographies